Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Metabolism And Diet for Improving Kidney Cancer Health (MACH3) (MACH3)

11 novembre 2026 mis à jour par: Tracy E Crane, PhD, RDN, University of Miami

The purpose of this study is to test whether a Mediterranean-style diet and a time-restricted eating plan ("intermittent fasting") are easy to follow and acceptable for people who were recently diagnosed with kidney cancer.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

30

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Tracy Crane, PhD
  • Numéro de téléphone: (305) 243-8255
  • E-mail: tecrane@miami.edu

Sauvegarde des contacts de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • 18 years of age or older
  • Speak and understand English or Spanish
  • New diagnosis of clear cell renal cell carcinoma (RCC) who will undergo treatment with immunotherapy or immunotherapy-based combination treatments in the following two settings at the discretion of the treating investigator:
  • Post-operative adjuvant
  • First-line metastatic setting

Immunotherapy treatments may include:

  • Pembrolizumab (adjuvant)
  • Ipilimumab/nivolumab (metastatic)
  • Pembrolizumab/Lenvatinib (metastatic)
  • Pembrolizumab/axitinib (metastatic)
  • Nivolumab/carbozantinib (metastatic)
  • Approval from medical oncologist to participate
  • No medical contraindications to immunotherapy or TKI therapy based on the treating physician's judgement

Exclusion Criteria:

  • Already consistently following Mediterranean or time-restricted eating ("intermittent fasting") eating pattern in the past 3 months

    1. Not equal to or more than 50% of the time) engaged in structured fasting (i.e., not regularly fasting for ≥12hr/night)
    2. Not equal to or more than 50% of the time consuming >5 servings of fruits/vegetables per day, 2 servings of fatty fish per week, 3 servings nuts/seeds per week, and using olive oil as the primary dietary oil/fat
  • Insulin-dependent diabetes or current use of glipizide

  • Uncontrolled medical conditions (including dialysis, hypertension, cardiac disease)

  • Oxygen dependence

  • Eastern Cooperative Oncology Group (ECOG) Performance status >3

  • Life expectancy <12 months

  • Estimated Glomerular Filtration Rate (EGFR) <40 mLs/min

  • History of autoimmune disorders, or contraindications to immunotherapy

  • Active, untreated CNS metastases (brain mets)

  • Psychiatric history of mental state which would negatively impact participation and adherence to the intervention, e.g. major psychiatric disease, clinical eating disorder

  • BMI <20 kg/m2

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Soins de soutien
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Arm 1: Intervention (MED+FAST)

All intervention participants will receive the MED+FAST intervention, which combines time-restricted eating and a Mediterranean diet.

All participants will receive weekly health coaching sessions during the intervention via telephone, video call, or in-person, as feasible. The health coach will contact the participant after randomization to begin the intervention, which will include education on intermittent fasting and following a Mediterranean diet. Sessions are expected to last approximately 30-45 minutes and can be divided per participant preference.

The intervention is designed to support participants in adopting timerestricted eating as part of their daily dietary routine. This approach is intended to modify the timing of food intake rather than reduce overall caloric intake, with participants encouraged to maintain their usual caloric intake within the prescribed eating window. Participants will be instructed to not consume any calorie-containing food/drinks after 8pm, or when their fasting window is scheduled per patient preference, and to wait 12-14 hours after the fasting start before resuming eating the next day.

The intervention also aims to support participants in adopting key components of the Mediterranean diet alongside their time-restricted eating goals. In addition to meeting time-restricted eating goals, weekly coaching sessions will encourage participants to adopt key components of a Mediterranean diet.

To enhance adherence and engagement, participants in the intervention arm will receive multiple forms of support to help them successfully implement time-restricted eating and Mediterranean diet goals

Aucune intervention: Arm 2: Waitlist Control with Usual Care

Participants randomized to the usual care arm will receive standard care with remote digital biomarker monitoring. Control participants will have the option to meet with the study health coach at the end of the 12-week study and will be directed to cancer survivorship services offered at Sylvester for additional support if requested.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Feasibility of Recruitment: Percentage of Participants That Consent to Participate and Meet Eligibility Criteria
Délai: Baseline

Feasibility of recruitment will reported as the percentage of participants who agree to participate (≥50%) at baseline.

Baseline
Feasibility of Retention and Adherence: Percentage of Participants Who Adhere to and Complete the Intervention and Data Collection at All Time Points.
Délai: Up to 12 weeks

Feasibility of retention and adherence will be reported as the percentage of intervention sessions completed (≥70%) at 12 weeks as measured by documented attendance/engagement each week with coach.

Up to 12 weeks
Acceptability: Percentage of Participants Who Report Satisfaction with the Intervention
Délai: Up to 12 weeks

Acceptability will be reported as the percentage of participants in the intervention arm of the study who report satisfaction with intervention (≥80%) at 12 weeks post-intervention as measured by 21-item participant satisfaction questionnaire, scores range from 0-5 with higher scores indicating greater satisfaction.

Up to 12 weeks

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Overall Response Rate (ORR)
Délai: Up to 12 weeks

Overall Response Rate (ORR) is the proportion of patients achieving complete response (CR) or partial response (PR) as the best response. ORR will be calculated as the proportion of participants achieving a complete or partial response at 12 weeks.

Up to 12 weeks
Number of Participants Experiencing Adverse Events (AEs)
Délai: Up to 12 weeks

Adverse events will be assessed using patient-reported and clinician-reported measures. The number of participants experiencing adverse events will be measured.

Up to 12 weeks
Change in Physical Function (Handgrip Strength)
Délai: Baseline, up to 12 weeks

Change in physical function (handgrip strength) will be assessed using a hand dynamometer. Percentage change in handgrip strength will be reported at baseline, 6 weeks, and 12 weeks by study arm.

Baseline, up to 12 weeks
Change in Diet As Assessed by the Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24)
Délai: Baseline, up to 12 weeks

Patient-reported outcomes for change in diet (ASA24) will be evaluated using the Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool. This assessment will generate a score derived from the Healthy Eating Index (HEI). HEI scores range from 0 to 100, where higher numbers reflect better overall diet quality.

Baseline, up to 12 weeks
Change in Physical Activity As Measured By Scores on the Godin Leisure Time Exercise Questionnaire
Délai: Baseline, up to 12 weeks

Change in participant quality of life in both the intervention and control groups as measured by the Godin Leisure Time Exercise Questionnaire will be reported. The Godin Leisure Time Exercise Questionnaire assesses participants' frequency of leisure activity/exercise (strenuous, moderate or light) for more than 15 minutes during a 7-day period. Higher scores (≥24) indicate a more active lifestyle and lower scores (≤23) indicate an insufficiently active lifestyle. Scores collected at baseline (T1) will be compared to scores collected 6 weeks (T2) and week 12 (T3).

Baseline, up to 12 weeks
Change in Quality of Life As Measured By Scores on the PROMIS-29 Questionnaire
Délai: Baseline, up to 12 weeks

Change in participant quality of life in both the intervention and control groups as measured by scores on the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) questionnaire will be reported. PROMIS-29 questionnaire is a 29-item validated measure using a single 0-10 numeric rating item with seven domains of health, including physical function, anxiety, depression, pain interference, fatigue, sleep disturbance, ability to participate in social roles and activities and pain intensity. Scores collected at baseline (T1) will be compared to scores collected at 6 weeks (T2) and 12 weeks (T3). Higher scores represent worse symptoms for symptom-oriented domains (anxiety, depression, fatigue, pain intensity, pain interference, and sleep disturbance) and better health outcomes for function-oriented domains (physical functioning and ability to participate in social roles and activities).

Baseline, up to 12 weeks
Change in Sleep Quality as Assessed by the Pittsburgh Sleep Quality Index
Délai: Baseline, up to 12 weeks

Patient-reported outcomes for change in sleep will be evaluated using the Pittsburgh Sleep Quality Index. The Pittsburgh Sleep Quality Index (PSQI) is a 19-item questionnaire used to measure the quality and patterns of sleep in adults. It evaluates sleep across seven component scores, which are summed to create a single global score ranging from 0 to 21 (where higher scores indicate poorer sleep quality).

Baseline, up to 12 weeks
Change in Physical Activity as Measured By Participant Accelerometry Data, in Steps Per Day
Délai: Baseline, 12 weeks

Participant physical activity will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3).

Physical activity measures will include average daily step count in steps per day.

Baseline, 12 weeks
Change in Physical Activity as Measured By Participant Accelerometry Data, in Minutes Per Day
Délai: Baseline, 12 weeks

Participant physical activity will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3).

Physical activity measures will include sedentary time; light-intensity physical activity (LPA); moderate-intensity physical activity (MPA); vigorous-intensity physical activity (VPA); and total physical activity all in minutes per day.

Baseline, 12 weeks
Change in Sleep as Measured By Participant Accelerometry Data, in Minutes Per Night
Délai: Baseline, 12 weeks

Participant sleep will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3).

Sleep measures will include total sleep time; wake after sleep onset (WASO); and time in bed by minutes per night.

Baseline, 12 weeks
Change in Sleep as Measured By Participant Percentage of Sleep Efficiency
Délai: Baseline, 12 weeks

Participant sleep will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3).

Sleep measures will include percentage of sleep efficiency.

Baseline, 12 weeks
Change in Sleep as Measured By Participant Accelerometry Data, in Awakenings Per Night
Délai: Baseline, 12 weeks

Participant sleep will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3).

Sleep measures will include number of awakenings in awakenings per night.

Baseline, 12 weeks
Change in Sleep as Measured By Participant Accelerometry Data, in Minutes
Délai: Baseline, 12 weeks

Participant sleep will be measured using accelerometer scores data obtained at baseline (T1) will be compared to data collected at 12 weeks (T3).

Sleep measures will include sleep onset latency in minutes.

Baseline, 12 weeks
Change in Anthropometrics
Délai: Baseline, 12 weeks

Changes in anthropometric measurements will be assessed using standard-of-care abdominal CT and MRI scans.

Anthropometric measures will include height in centimeters (cm); body weight in kilograms (kg); body mass index (BMI) in kilograms per meter squared (kg/m^2); waist circumference in cm; hip circumference in cm; waist-to-hip ratio (if calculated).

Baseline, 12 weeks
Change in Body Composition
Délai: Baseline, 12 weeks

Changes in body composition characteristics will be assessed using standard-of-care abdominal CT and MRI scans.

Omron BIA measures will include percentage of total body fat; percentage of skeletal muscle; and visceral fat rating (unitless).

CT-derived composition measures will include skeletal muscle cross-sectional area in cm^2; skeletal muscle index (SMI) in cm^2/m^2; visceral adipose tissue are (VAT) in cm^2; subcutaneous adipose tissue are (SAT) in cm^2; skeletal muscle radiodensity in Hounsfield units (HU); and intramuscular adipose tissue area in cm^2.

Baseline, 12 weeks

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Tracy Crane, PhD, University of Miami

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

21 décembre 2026

Achèvement primaire (Estimé)

21 décembre 2030

Achèvement de l'étude (Estimé)

21 décembre 2030

Dates d'inscription aux études

Première soumission

21 octobre 2026

Première soumission répondant aux critères de contrôle qualité

11 novembre 2026

Première publication (Réel)

18 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner